6-(2-{(E)-2-[4-(2-dimethylamino-ethoxy)-phenyl]-vinyl}-pyridin-4-yl)-3,7-dihydro-pyrrolo[2,3 d]pyrimidin-4-one | 933986-84-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 6-(2-{(E)-2-[4-(2-dimethylamino-ethoxy)-phenyl]-vinyl}-pyridin-4-yl)-3,7-dihydro-pyrrolo[2,3 d]pyrimidin-4-one
• 英文别名: Pyrrolo-pyrimidone, 17；6-[2-[(E)-2-[4-[2-(dimethylamino)ethoxy]phenyl]ethenyl]pyridin-4-yl]-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one
• CAS: 933986-84-6
• 化学式: C₂₃H₂₃N₅O₂
• 分子量: 401.468
• InChiKey: RLAJOHAIIACFAM-ZZXKWVIFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  82.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2
  申请人：Heng Richard

  公开号：US20090169558A1

  公开（公告）日：2009-07-02

  A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: wherein the groups R1-R6, A and Y are as defined in the specification.

  化合物的化学式(I)或其药学上可接受的盐或前药酯：其中，基团R1-R6，A和Y的定义如规范所述。
• Compositions and Methods for Treating Cutaneous Scarring
  申请人：Lander Cynthia

  公开号：US20140072613A1

  公开（公告）日：2014-03-13

  The described invention provides compositions, dressings and methods for treating a cutaneous scar in a subject. The compositions of the derived invention contains a pharmaceutical composition comprising a therapeutic amount of a Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK2) inhibitor comprising an MK2 polypeptide inhibitor or a functional equivalent thereof, and a pharmaceutically acceptable carrier.
• FORMULATION OF MK2 INHIBITOR PEPTIDES
  申请人：MOERAE MATRIX, INC.

  公开号：US20160200782A1

  公开（公告）日：2016-07-14

  The described invention provides pharmaceutical formulations comprising a polypeptide of amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent thereof with improved stability and bioavailability.
• USE OF MKS INHIBITOR PEPTIDE-CONTAINING COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER WITH SAME
  申请人：Moerae Matrix, Inc.

  公开号：US20160263187A1

  公开（公告）日：2016-09-15

  The described invention provides pharmaceutical compositions, systems and methods for treating a non-small cell lung cancer (NSCLC) solid tumor comprising a population of tumor cells. The method includes administering a pharmaceutical composition comprising a therapeutic amount of a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, wherein therapeutic amount of the polypeptide is effective to inhibit a kinase activity in the population of tumor cells and to reduce cancer cell proliferation, to reduce tumor size, to reduce tumor burden, to induce tumor cell death, to overcome tumor chemoresistance, to enhance tumor chemosensitivity, or a combination thereof.
• USE OF MK2 INHIBITOR PEPTIDE-CONTAINING COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER WITH SAME
  申请人：Moerae Matrix, Inc.

  公开号：US20190022176A1

  公开（公告）日：2019-01-24

  The described invention provides pharmaceutical compositions, systems and methods for treating a solid tumor comprising a population of tumor cells. The method includes administering a pharmaceutical composition comprising a therapeutic amount of a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, wherein therapeutic amount of the polypeptide is effective to inhibit a kinase activity in the population of tumor cells and to reduce cancer cell proliferation, to reduce tumor size, to reduce tumor burden, to induce tumor cell death, to overcome tumor chemoresistance, to enhance tumor chemosensitivity, or a combination thereof.